<DOC>
	<DOCNO>NCT01728454</DOCNO>
	<brief_summary>The primary objective study determine safety efficacy two oral dos Proellex administer premenopausal woman pelvic pain associate endometriosis confirm within last seven year use prescription analgesic symptomatic pain .</brief_summary>
	<brief_title>The Evaluation Safety Efficacy Proellex Treatment Pre-Menopausal Women With Confirmed , Symptomatic Endometriosis</brief_title>
	<detailed_description>This study phase 2 , 3-arm-study 18 week active dosing period option subject receive 2 additional 16-week cycle active treatment randomize dose ( 6 mg 12 mg/day ) . Placebo subject elect additional treatment receive treatment 12 mg/day . The treatment dose remain double-blind . The study conduct 3 stage . In first stage , woman receive daily single-blind placebo . This stage last long take record least one full menstrual cycle ( ovulation ovulation ) . For stage 2 , follow run-in stage , Visit 3 , 60 subject randomize one 3 arm 1-1-1 fashion . The start dose commence soon possible ovulation follow end previous menstrual event . For stage 3 , subject eligible receive additional cycle treatment elect continue treatment schedule within week second expect menses ( +/- 2 day ) , follow off-drug interval . Subjects receive 2 cycle treatment separate off-drug interval ( ODI ) , follow menses return .</detailed_description>
	<mesh_term>Endometriosis</mesh_term>
	<criteria>Healthy adult female 18 47 year age use prescription analgesic endometriosis pain BBSS score ≥7 screening ( assess previous 28 day , see Appendix 2 ) . Endometriosis diagnosis must surgically confirm within 7 year . A laparoscopic diagnosis acceptable . Subjects must history least 3 regular menstrual cycle symptom endometriosis occur immediately prior screen Normal abnormal nonclinically significant transvaginal ultrasound History menstrual event occur regular cycle Agreement attempt become pregnant trial Agreement limit alcohol consumption 2 drink per week avoid alcohol consumption within 48 hour visit Ability complete daily electronic subject diary study procedure compliance protocol Women childbearing potential must willing use doublebarrier contraception study 30 day discontinuation study medication . Acceptable doublebarrier method : male condom spermicide ; male condom diaphragm ; diaphragm contain spermicide plus additional intravaginal spermicide Has negative pregnancy test Screening Baseline visit , subsequent study visit A Body Mass Index ( BMI ) 18 39 inclusive Is available treatment followup visit Subject postmenopausal woman , define either ; six ( 6 ) month ( immediately prior screen visit ) without menstrual period , prior hysterectomy and/or oophorectomy . Subject pregnant lactating attempt expect become pregnant 67 month study period Women abnormally high liver enzymes liver disease . ( ALT ( alanine transaminase ) AST ( aspartate aminotransferase ) exceed 2 x ULN ( upper limit normal ) AND total bilirubin exceed 1.5x ULN screening confirm repeat ) . Received investigational drug 30 day prior screen study Women history PCOS ( polycystic ovary syndrome ) Concurrent use testosterone , androgen , anabolic steroid , DHEA ( dehydroepiandrosterone ) hormonal product least 2 week prior screen study . Oral contraceptive use control endometriosis symptom acceptable first 28days study . Use DepoProvera® precede 6 month . Use GnRHas ( e.g . Lupron Depot ) within 3 month first dose study drug ( Lupron Depot must washout period 3 month period duration Lupron dose ) . Has IUD ( intrauterine device ) place . Copper IUDs ( nonhormone contain permit ) . Presence intramural fibroid impact endometrial stripe , submucosal fibroid ( size ) , endometrial polyp . Subserosal intramural fibroid impact endometrial stripe acceptable . Presence endometrioma ( ) Present history condition cause nonendometriosis relate dyspareunia ( e.g . vulvar vestibulitis ) . Past present history thrombophlebitis thromboembolic disorder . Known suspect carcinoma breast reproductive organ . History abnormal ECG , opinion investigator , clinically significant prevent subject complete study , include QTc ( correct QT interval ) great 450 ms. Cervical dysplasia classify Atypical Squamous Cells Undetermined Significance ( ASCUS ) associate highrisk human papilloma virus ( HPV ) Low/High Grade Squamous Intraepithelial Lesion ( LGSIL HGSIL ) . History abnormal endometrial biopsy include presence EIN ( Endometrial Intraepithelial Neoplasia ) . Recent history ( within past 6 month ) alcoholism drug abuse . Known active infection HIV , Hepatitis A , B C. Previous history autoimmune disease and/or positive antinuclear antigen ( ANA ) . Endometrial stripe ≥18 mm thickness Visit 1 . Women currently take cimetidine spironolactone . Clinically significant abnormal finding screen examination laboratory assessment condition opinion investigator would interfere participant 's ability comply study instruction endanger participant take part study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>47 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>